Pegfilgrastim ANF

Drug Profile

Pegfilgrastim ANF

Alternative Names: ANF-Rho™; PEG G CSF ANF; Pegfilgrastim anti-neutropenic factor; Pegylated recombinant human granulocyte colony stimulating factor

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Prolong Pharmaceuticals
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 21 Dec 2016 Phase-II clinical trials in Neutropenia (Chemotherapy-induced, Prevention) in Netherlands (SC) (EudraCT2016-001965-98)
  • 03 Jun 2016 Pharmacokinetics and pharmacodynamics data from a phase I trial in healthy volunteers presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top